Mutations in DNA binding domain of p53 impede RSL1D1-p53 interaction to escape from degradation in human colorectal cancer cells

Potential prognostic biomarkers of hepatocellular carcinoma based on 4D label-free quantitative proteomics analysis pilot investigation

“…27 Ribosomal L1 domain containing 1 (RSL1D1), a UL1 ribosomal protein, plays an important role in autophagy and progression of colorectal cancer. [28][29][30] However, the role of RSL1D1 in cancer remains elusive. RSL1D1 promotes proliferation, invasion, and metastasis of colorectal cancer cells by inhibiting autophagy.…”

The importance of protein domain mutations in cancer therapy

“…Protein domains frequently mediate protein-protein interactions; mutations in these domains can change a protein's capacity to interact with other proteins [ 93 ]. For instance, a mutation in the DNA-binding region of the p53 gene at position R175H can block the interaction of RSL1D1 and p53 and activate downstream tumor-suppressing pathways, resulting in colorectal cancer [ 94 , 95 ]. Similarly, mutations in the exons 18–21 of EGFR allow the kinase domain to interact abnormally with downstream signalling molecules through the PI3K/AKT and MAPK/RAF pathways, resulting in uncontrolled cell proliferation [ 96 , 97 ].…”